Just under 50% of asthma patients on high-dose LABA/ICS remain uncontrolled1
of patients with asthma remain uncontrolled, despite current treatment with high-dose LABA/ICS*1
Persistence of symptoms puts patients at a higher risk of asthma attacks2
*Baseline data from a retrospective study of 45,804 adult asthma patients in the UK, newly initiated on medium- or high-dose LABA/ICS therapy.1
Indication: ENERZAIR® BREEZHALER® (indacaterol acetate/glycopyrronium bromide/mometasone furoate inhalation powder) is indicated as a maintenance treatment for asthma in adult patients not adequately controlled with a maintenance combination of a long-acting beta2-agonist and a high dose of an inhaled corticosteroid, who experienced one or more asthma exacerbations in the previous year.3
ICS, inhaled corticosteroid; LABA, long-acting beta2-agonist.
- Buhl R et al. Respir Med 2020;162:105859 [Epub ahead of print].
- Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, 2020. Available at: https://ginasthma.org/wp-content/uploads/2020/04/GINA-2020-full-report_-.... Date accessed: December 2020.
- ENERZAIR BREEZHALER Summary of Product Characteristics.